184 related articles for article (PubMed ID: 32433714)
21. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
22. POLE/POLD1 mutation and tumor immunotherapy.
Ma X; Dong L; Liu X; Ou K; Yang L
J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
[TBL] [Abstract][Full Text] [Related]
23. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
24. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer.
Kikuchi E; Yamazaki K; Torigoe T; Cho Y; Miyamoto M; Oizumi S; Hommura F; Dosaka-Akita H; Nishimura M
Cancer Sci; 2007 Sep; 98(9):1424-30. PubMed ID: 17645781
[TBL] [Abstract][Full Text] [Related]
25. Antigen-Presenting Intratumoral B Cells Affect CD4
Bruno TC; Ebner PJ; Moore BL; Squalls OG; Waugh KA; Eruslanov EB; Singhal S; Mitchell JD; Franklin WA; Merrick DT; McCarter MD; Palmer BE; Kern JA; Slansky JE
Cancer Immunol Res; 2017 Oct; 5(10):898-907. PubMed ID: 28848053
[TBL] [Abstract][Full Text] [Related]
26. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
Massarelli E; Lam VK; Parra ER; Rodriguez-Canales J; Behrens C; Diao L; Wang J; Blando J; Byers LA; Yanamandra N; Brett S; Morley P; Sharma P; Allison J; Wistuba II; Heymach JV
J Immunother Cancer; 2019 Dec; 7(1):351. PubMed ID: 31843013
[TBL] [Abstract][Full Text] [Related]
27. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers.
Wakabayashi O; Yamazaki K; Oizumi S; Hommura F; Kinoshita I; Ogura S; Dosaka-Akita H; Nishimura M
Cancer Sci; 2003 Nov; 94(11):1003-9. PubMed ID: 14611679
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Molecular Characterization of
Garmezy B; Gheeya J; Lin HY; Huang Y; Kim T; Jiang X; Thein KZ; Pilié PG; Zeineddine F; Wang W; Shaw KR; Rodon J; Shen JP; Yuan Y; Meric-Bernstam F; Chen K; Yap TA
JCO Precis Oncol; 2022 Feb; 6():e2100267. PubMed ID: 35108036
[TBL] [Abstract][Full Text] [Related]
29. CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells.
Rogers RF; Walton MI; Cherry DL; Collins I; Clarke PA; Garrett MD; Workman P
Cancer Res; 2020 Apr; 80(8):1735-1747. PubMed ID: 32161100
[TBL] [Abstract][Full Text] [Related]
30. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of CD8
Obeid JM; Wages NA; Hu Y; Deacon DH; Slingluff CL
Cancer Immunol Immunother; 2017 Jan; 66(1):33-43. PubMed ID: 27770170
[TBL] [Abstract][Full Text] [Related]
32. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
[TBL] [Abstract][Full Text] [Related]
33. Phenotype of POLE-mutated endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Rau TT; Mueller MD; Epstein E; Carlson JW
PLoS One; 2019; 14(3):e0214318. PubMed ID: 30917185
[TBL] [Abstract][Full Text] [Related]
34. Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing.
Lasabová Z; Kalman M; Holubeková V; Grendár M; Kašubová I; Jašek K; Meršaková S; Malicherová B; Baranenko D; Adamek M; Kruzliak P; Plank L
Clin Exp Med; 2019 Aug; 19(3):393-400. PubMed ID: 31049795
[TBL] [Abstract][Full Text] [Related]
35. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
36. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
[TBL] [Abstract][Full Text] [Related]
37. NFATc1 Promotes Antitumoral Effector Functions and Memory CD8
Heim L; Friedrich J; Engelhardt M; Trufa DI; Geppert CI; Rieker RJ; Sirbu H; Finotto S
Cancer Res; 2018 Jul; 78(13):3619-3633. PubMed ID: 29691251
[TBL] [Abstract][Full Text] [Related]
38. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
Talebian Yazdi M; van Riet S; van Schadewijk A; Fiocco M; van Hall T; Taube C; Hiemstra PS; van der Burg SH
Oncotarget; 2016 Jan; 7(3):3477-88. PubMed ID: 26658106
[TBL] [Abstract][Full Text] [Related]
39. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
40. Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
Fang H; Barbour JA; Poulos RC; Katainen R; Aaltonen LA; Wong JWH
PLoS Genet; 2020 Feb; 16(2):e1008572. PubMed ID: 32012149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
